Biotech Archives - Page 674 of 795

3 minute read

Better Therapeutics Highlights Publication Of BT-001 Trial In ADA Diabetes Care Journal

October 4, 7:32 AM

)-- Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today

BTTX

2 minute read

Autolus Therapeutics Announces Collaboration With Bristol Myers Squibb For Use Of Autolus’ Safety Switch System

By Bill Haddad

October 4, 7:09 AM

- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development

AUTL

2 minute read

Aeglea BioTherapeutics Provides Clinical Progress And Regulatory Update For Homocystinuria Program

By Benzinga Newsdesk

October 4, 7:05 AM

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing

AGLE

1 minute read

UPDATE: Voyager Eligible For Up To $290M In Associated Milestone Payments

By Bill Haddad

October 4, 7:03 AM

Under the terms of the license option agreement, originally announced in October 2021, Voyager previously received a $30 million upfront payment and is entitled to receive a $10 million option exercise payment. Voyager

PFE

3 minute read

Connect Biopharma Reports CBP-201 Achieved All Primary And Key Secondary Endpoints In Pivotal Atopic Dermatitis (AD) Trial In China

By Bill Haddad

October 4, 7:01 AM

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the

CNTB

3 minute read

ChromaDex Announces Findings From Study On Safety And Tolerability Of Nicotinamide Riboside In Heart Failure With Reduced Ejection Fraction

By Bill Haddad

October 4, 6:34 AM

This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research LOS ANGELES--(BUSINESS

CDXC

2 minute read

KalVista Pharmaceuticals Announces Termination Of KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of Hereditary Angioedema

By Bill Haddad

October 4, 6:31 AM

- Safety signals observed will not yield targeted product profile – - No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial – - Oral Factor XIIa program to become primary

KALV

1 minute read

Adamis Pharmaceuticals Seeks Strategic Options, Including Sale

By Vandana Singh

October 4, 6:27 AM

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has initiated a process to explore a range of strategic and financing alternatives. The move follows the recently…

ADMP

1 minute read

The European Commission Authorized the Conversion of the Conditional Marketing Authorization for Moderna’s Spikevax to Standard Marketing Authorization

By Charles Gross

October 4, 5:52 AM

https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates

MRNA

1 minute read

Connect Biopharma To Host A Conference Call Tuesday, October 4 To Discuss Topline Results For The Pivotal Trial In China Of Lead Candidate, CBP-201, In Patients With Moderate-To-Severe Atopic Dermatitis

By Benzinga Newsdesk

October 3, 4:21 PM

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited

CNTB